THE WOODLANDS, Texas--(BUSINESS WIRE)--On November 6, 2009, Repros Therapeutics Inc. (NasdaqGM:RPRX) received notification from NASDAQ that it has not regained compliance with NASDAQ Listing Rules 5450(b)(2)(A) or 5450(b)(3)(A) and, unless the Company appeals NASDAQ’s decision, its securities will be delisted from the NASDAQ Global Market. Repros intends to appeal NASDAQ’s determination to delist its securities or, alternatively, to request to have its securities moved to the NASDAQ Capital Market. There can be no assurance that either of these strategies will be successful.
